Applied Protein Sciences, LLC (APS) is a Silicon Valley based biopharmaceutical company primarily focused on preventing and treating mucositis - one of the most debilitating side effects of current cancer treatments involving radiation and chemotherapy. APS has uncovered and tested novel proprietary compounds that have shown tremendous potential to be the defacto "Standard of Care" for supportive oncology treatments.

APS most advanced product is the novel peptide AP002 which is on target to complete all preclinical testing and be ready for Phase I clinical trials.

APS' proprietary protein compounds are protected through 6 issued US patents, a strong international patent portfolio. These compounds help in the growth of the regeneration of epithelial stem cells and hence can find applications for various therapeutic indications. APS product pipeline consists of drug candidates for:

• Oral Mucositis
• GI Mucositis
• Proctitis
• Ulcerative Colitis
• Inflammatory Bowel Disease (IBD)

Our experienced management team, researchers, academics, practicing clinicians and development partners have extensive experience in developing pre-clinical and clinical programs for mucositis, which promise an early clinical validation and a reduced time to market.